Indian drugmakers Eris Lifesciences, Wockhardt and Lupin are prepping to cash in when Danish company Novo Nordisk bows out of the human insulin pen market by the end of this year and creates an opportunity estimated to be worth Rs 600-800 crore in the domestic market. Some self-use disposable pens are pre-filled with insulin and others can be reused with new cartridges.
The FDA had imposed a ban on the company's Waluj plant in May.
If the company manages to get a go-ahead from the regulator for this plant, it might result in resumption of supplies of several of their products, barred from the US last year.
Wockhardt MD Murtaza Khorakiwala said his firm had responded to the FDA's observations but declined to give details.
'There are different kinds of risk.' 'It is a very powerful value. Your ability to de-risk the risk is also as important for risk taking.'
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances